GLP-1 receptor agonists were originally developed for type 2 diabetes. That's where drugs like Ozempic got their start. But once researchers noticed patients losing substantial weight on these medications, the pharmaceutical companies pursued separate FDA approvals specifically for obesity. The result is a confusing situation where the same active ingredient, semaglutide, for example, is sold under different brand names for different conditions. (See our semaglutide guide.)
Same Drug, Different Label
The clearest example is semaglutide. Ozempic is FDA-approved for type 2 diabetes. Wegovy is FDA-approved for chronic weight management. Both are injectable semaglutide made by Novo Nordisk. The same split exists with tirzepatide: Mounjaro treats diabetes, while Zepbound targets weight loss.
This isn't just a branding exercise. The dosing schedules differ. Wegovy's recommended maintenance dose is 2.4 mg as a weekly injection, while Ozempic tops out at 2 mg. The label allows an increase to 7.2 mg weekly (Wegovy HD) for adults who have tolerated 2.4 mg for at least four weeks when additional weight reduction is clinically indicated. Zepbound and Mounjaro use the same starting dose (2.5 mg), the same step-ups (2.5 mg at least every 4 weeks) and the same 15 mg maximum. Zepbound's label names 5, 10 or 15 mg as maintenance doses for weight loss.
Why the Distinction Matters for Insurance
Insurance coverage is where this gets practical. Most commercial insurance plans cover diabetes medications without much pushback, type 2 diabetes is a well-established diagnosis with clear treatment guidelines. Weight loss medications are a different story. Many insurers still classify obesity drugs as "lifestyle" treatments and exclude them from coverage, even though obesity is recognized as a chronic disease by every major medical organization. (See our GLP-1 insurance coverage guide.)
Medicare is a good example of the gap. Standard Part D covers Ozempic for diabetes patients and Wegovy for its heart-risk indication, but not weight loss on its own. Since July 1, 2026, the Medicare GLP-1 Bridge, a CMS demonstration that runs to December 31, 2027, covers Wegovy, the Zepbound KwikPen and Foundayo for obesity at a $50 copay for beneficiaries who meet its BMI-based criteria. Type 2 diabetes, moderate to severe obstructive sleep apnea and noncirrhotic MASH with moderate to advanced liver scarring (fibrosis) are not Bridge indications; they are eligible indications under standard Part D instead, subject to your plan's usual rules. See our Medicare guide. Medicaid is state by state: covering GLP-1s for weight loss is optional, and several states, including California and Massachusetts, have recently stopped. Coverage for type 2 diabetes is handled separately and is much more common. If cost is a concern, our clinic price report shows what clinics advertise, next to what the drug makers charge. (See our Medicaid GLP-1 coverage.)
Off-Label Prescribing
Because of coverage gaps, some doctors prescribe Ozempic off-label for weight loss. This is legal, doctors can prescribe any FDA-approved drug for any condition they believe is medically appropriate. But there are trade-offs. You might get a lower dose than you'd receive with Wegovy, and if your insurer audits the claim, you could face problems.
Some clinics are upfront about this approach. Others won't do it at all. It's worth asking directly when you're shopping for a provider. You can search our clinic directory and ask during a consultation what their prescribing approach is.
Eligibility Criteria Differ
For diabetes, the prescribing criteria are straightforward: you have type 2 diabetes, and your doctor decides a GLP-1 is appropriate for blood sugar management. For weight loss, FDA guidelines require a BMI of 30 or higher, or 27+ with at least one weight-related condition like high blood pressure, sleep apnea, or high cholesterol. Check our BMI calculator if you're not sure where you stand.
Patients with both diabetes and obesity are in a unique position. Their doctor might prescribe a diabetes-labeled GLP-1 that also helps with weight, getting insurance to cover a medication that accomplishes both goals. This is actually a common and legitimate prescribing strategy.
Which One Should You Ask About?
If you have type 2 diabetes, your endocrinologist or primary care doctor will likely start with the diabetes-approved version. If weight loss is your primary goal and you don't have diabetes, you'll want a provider who prescribes Wegovy or Zepbound specifically. The active ingredients work the same way in your body. They slow gastric emptying, reduce appetite, and act on brain receptors that control hunger. The real differences come down to dosing, insurance coding, and which condition your doctor documents as the primary diagnosis.